Dyskinesia
Dyskinesia top experts.
Open the FULL List in Excel
Showing results 1 to 50 from more than 100,000 results:
Dyskinesia: Top KOLs in the world
| World Rank | Name | Topic | PersonRank Score | |
#1 | Jonathan ******* ******** (Reveal full name) Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada. | Toronto Western Hospital, University Health Network, Krembil Neuroscience Centre, Toronto, Canada | Toronto Western Hospital, University Health Ne
| Dyskinesia | Reveal score | |
#2 | Susan * *** (Reveal full name) Edmond J. Safra Program in Parkinson's Disease, Rossy Progressive Supranuclear Palsy Centre, Movement Disorders Clinic, Krembil Brain Institute, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, Tor
| Dyskinesia | Reveal score | |
#3 | Robert * ****** (Reveal full name) Parkinson’s Disease and Movement Disorders Center, Department of Neurology, Parkinson Foundation Center of Excellence, University of South Florida, 4001 E Fletcher Ave, Tampa, FL 33613, USA, usf.edu | USF Parkinson’s Disease and Movement Disorders Ce
| Dyskinesia | Reveal score | |
#4 | Maria ****** ***** (Reveal full name) Basal Ganglia Pathophysiology Unit, Dept. Experimental Medical Science, Lund University, Sweden. Electronic address: Angela.Cenci_Nilsson@med.lu.se. | Basal Ganglia Pathophysiology Unit, Department of Experimental Medical Science, Lund University, 22
| Dyskinesia | Reveal score | |
#5 | Alan * ******** (Reveal full name) University of Manchester, Manchester M13 9PL, UK. | Motac Neuroscience, Manchester, M15 6WE, United Kingdom | University of Manchester, Manchester, UK | Faculty of Life Sciences, University of Manchester, Manchester M13 9PL, UK | Faculty of Life Scie
| Dyskinesia | Reveal score | |
#6 | Thére`se ** ***** (Reveal full name) Faculté de pharmacie, Pavillon Ferdinand-Vandry, 1050, avenue de la Médecine, Université Laval, Québec (Québec) G1V 0A6, Canada | Neuroscience Research Unit, CHU de Québec Research Centre and the Faculty of Pharmacy, Laval University, Québec City, Qu
| Dyskinesia | Reveal score | |
#7 | Joseph * ******** (Reveal full name) Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA | Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Housto
| Dyskinesia | Reveal score | |
#8 | José ***** ***** (Reveal full name) Universidad San Pablo-CEU, Madrid, Spain. | CIBERNED, Instituto de Salud Carlos III, Madrid, Spain. | HM CINAC (Centro Integral de Neurociencias Abarca Campal), Fundación Hospitales de Madrid, Hospital Universitario HM Puerta del Sur, HM Hospitales,
| Dyskinesia | Reveal score | |
#9 | Christopher * ***** (Reveal full name) Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA. | Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States. | Rush University Medical Center, Chicago, Illinois, USA | Rush
| Dyskinesia | Reveal score | |
#10 | Olivier ****** (Reveal full name) Toulouse Parkinson Expert Center, Departments of Neurosciences and Clinical Pharmacology, Centre d’Investigation Clinique de Toulouse CIC1436, NS-Park/FCRIN Network, and NeuroToul COEN Center, University Hospital of Toulouse, INSERM, University of To
| Dyskinesia | Reveal score | |
#11 | Thomas * ***** (Reveal full name) KM Pharmaceutical Consulting LLC, Washington, DC 20006, USA;, tchase@chasetherapeutics.com, (T.N.C.);, mkoga@kmphc.com, (M.K.) | KM Pharmaceutical Consulting LLC, Washington, District of Columbia | Chase Pharmaceuticals, Inc, 1825 K Street NW, Washin
| Dyskinesia | Reveal score | |
#12 | Charles * ****** (Reveal full name) Clintrex Research Corp, Sarasota, FL, USA | Mount Sinai School of Medicine, New York, NY, USA; Clintrex, Research Corporation, Sarasota, FL, USA. Electronic address: warren.olanow@clintrex.com. | Clintrex Research Corporation, Sarasota, Florida, USA
| Dyskinesia | Reveal score | |
#13 | Stanley **** (Reveal full name) Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA | Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA | H. Houston Merritt Professor Emeritus of
| Dyskinesia | Reveal score | |
#14 | Anthony ****** **** (Reveal full name) Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and Division of Neurology, UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada | Department of Me
| Dyskinesia | Reveal score | |
#15 | Andrew **** ****** (Reveal full name) Reta Lila Weston Institute, Institute of Neurology, UCL and National Hospital, Queen Square, London, United Kingdom | Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, London, UK | University Colle
| Dyskinesia | Reveal score | |
#16 | John * **** (Reveal full name) Department of Neurology, Oregon Health and Science University, Portland, OR, USA. | Movement Disorder Section, Department of Neurology, Oregon Health & Science University, Portland, OR, USA | Department of Neurology, Oregon Health and Science Univers
| Dyskinesia | Reveal score | |
#17 | Werner * ***** (Reveal full name) Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria | Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria | Department of Neurology, Innsbruck Medical University, Innsbruck, Austria | Department of
| Dyskinesia | Reveal score | |
#18 | C ***** ******* (Reveal full name) MRC Movement Disorders Research Group, University Department of Neurology and Parkinson's Disease Society Research Centre, Institute of Psychiatry and King's College Hospital Medical School, Denmark Hill, London SE5 8AF, UK | M.R.C. Movement Disorder
| Dyskinesia | Reveal score |
Amantadine Er (Gocovri®) Significantly Increases On Time Without Any Dyskinesia:...
.. levodopa-induced dyskinesias (LID) into "troublesome" and "non-troublesome" categories. Yet, given the choice, most patients would prefer to live without experiencing any dyskinesia. ...
| star star star star star |
| Also Ranks for: Time Dyskinesia | motor complications | parkinsons disease | week 12 | placebo adjusted |
Factors Associated With Dyskinesia In Parkinson's Disease In Mainland China
.. for dyskinesia in Parkinson's disease (PD) have been inconsistent, and racial differences exist. Since there have been no systematic studies of the characteristics of dyskinesia in the ...
| star star star star star |
| Also Ranks for: Risk Factors Dyskinesia | parkinsons disease | motor complications | daily dose | updrs iii |
Animal Models Of L-Dopa–induced Dyskinesia: An Update On The Current Options
.. (dyskinesia) affect a majority of the patients after a few years of L-DOPA treatment and can become troublesome and debilitating. Once dyskinesia has debuted, an irreversible process seems ...
| star star star star star_half |
| Also Ranks for: Animal Models | induced dyskinesia | current options | motor complications | ldopa treatment |
Gdnf Reverses Priming For Dyskinesia In Mptp‐treated, L‐dopa‐primed Common Marmosets
.. of dyskinesia. In rodent and primate studies, glial cell line-derived neurotrophic factor (GDNF) may prevent 6-OHDA- or MPTP-induced nigral degeneration and so may be beneficial in the ...
| star star star star star_half |
| Also Ranks for: Substantia Nigra | locomotor activity | caudate nucleus | treated animals | induced dyskinesia |
Dopamine Receptors And Bdnf-Haplotypes Predict Dyskinesia In Parkinson's Disease
.. OBJECTIVE: Dyskinesia is a known side-effect of the treatment of Parkinson's Disease (PD). We examined the influence of haplotypes in three dopamine receptors (DRD1, DRD2 and DRD3) and the ...
| star star star star star_half |
| Also Ranks for: Parkinsons Disease | aged parkinson | receptors dopamine | derived neurotrophic | factor bdnf |